Century Therapeutics Selected for Oral Presentation of CNTY‑813 Preclinical Data at the American Diabetes Association 86th Scientific Sessions
Century Therapeutics announced it will deliver an oral presentation on preclinical data for CNTY-813, its iPSC-derived islet cell therapy for type 1 diabetes, at the upcoming ADA Scientific Sessions. The presentation will highlight the program's use of the Allo-Evasion™ 5.0 engineering technology, which aims to enable off-the-shelf therapies without chronic immunosuppression.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.